NPPB and hydrops fetalis: The PROVE-HF trial, a prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril-valsartan therapy for HF, found that patients with HFrEF treated with sacubitril-valsartan experienced a rapid reduction in NT-proBNP, a well-established biomarker for HF severity and prognosis.